

MPNs and GVHD

| | | Clinical Proof of Concept | Pivotal | Approved |
|---|---|---------------------------|---------|----------|
| Jakafi® (ruxolitinib) ¹ JAK1/JAK2 | Myelofibrosis ² , polycythemia vera ² , GVHD ² | | | |
| ruxolitinib XR (QD) JAK1/JAK2 | Bioequivalence and stability testing | | | |
| axatilimab ³ CSF-1R | Chronic GVHD | | | |
| zilurgisertib ALK2 | Anemia due to hematological disorders including MF ± ruxolitinib | | | |
| INCB57643 BET | Myelofibrosis ± ruxolitinib | | | |
| INCA33989 mutCALR | Myelofibrosis, essential thrombocythemia ± ruxolitinib | | | |

Dermatology and Other IAI

| | | | | |
|--|---|--|--|--|
| Opzelura® (ruxolitinib) cream JAK1/JAK2 | AD ² , vitiligo ^{2,4} | | | |
| ruxolitinib cream JAK1/JAK2 | Pediatric AD, prurigo nodularis | | | |
| | Hidradenitis suppurativa, lichen planus, lichen sclerosus | | | |
| povorcitinib JAK1 | Hidradenitis suppurativa, vitiligo | | | |
| | Prurigo nodularis, chronic spontaneous urticaria, asthma | | | |
| zilurgisertib ALK2 | Fibrodysplasia ossificans progressiva | | | |

Partnered Programs

| | | | | |
|---|--|--|--|--|
| Olumiant® (baricitinib) ⁵ JAK1/JAK2 | Rheumatoid arthritis ⁶ , COVID-19 ⁶ , AD ^{4,7} , alopecia areata ^{2,4,7} | | | |
| Tabrecta® (capmatinib) ⁸ MET | NSCLC with METex14 ⁶ | | | |
| capmatinib ⁸ MET | Liver cancer | | | |

General Hematology/Oncology

| | | Clinical Proof of Concept | Pivotal | Approved |
|--|--|---------------------------|---------|----------|
| Pemazyre® (pemigatinib) FGFR1/2/3 | 2L+ cholangiocarcinoma ⁹ , MLNs with FGFR1 rearrangement ^{2,7} | | | |
| Monjuvi® (tafasitamab-cxix) ¹⁰ Minjuvi® (tafasitamab) ¹⁰ CD19 | r/r DLBCL ^{2,4,11} | | | |
| Iclusig® (ponatinib) ¹² BCR-ABL | Chronic myeloid leukemia ⁴ , Ph+ ALL ⁴ | | | |
| Zynyz® (retifanlimab-dlwr) ¹³ PD-1 (mAb) | Merkel cell carcinoma ² | | | |
| pemigatinib FGFR1/2/3 | 1L cholangiocarcinoma | | | |
| | Glioblastoma | | | |
| tafasitamab ¹⁰ CD19 | 1L DLBCL, r/r follicular lymphoma, r/r MZL | | | |
| retifanlimab ¹³ PD-1 (mAb) | Squamous cell anal carcinoma, NSCLC | | | |
| | MSI-H endometrial cancer | | | |
| itacitinib JAK1 | Cytokine release syndrome | | | |
| INCB99280 PD-L1 (small molecule) | Cutaneous squamous cell carcinoma, solid tumors | | | |
| INCB99318 PD-L1 (small molecule) | Solid tumors | | | |
| INCAGN2385 ¹⁴ LAG-3 | Solid tumors | | | |
| INCAGN2390 ¹⁴ TIM-3 | Solid tumors | | | |
| INCA32459 ¹⁵ LAG-3×PD-1 | Advanced malignancies | | | |
| INCA33890 ¹⁵ TGFβR2×PD-1 | Solid tumors | | | |
| INCB123667 CDK2 | Solid tumors | | | |

17 Molecular Targets

22 Clinical Compounds

8 Approved Products

Updated as of October 31, 2023

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners.

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in Europe 5. Worldwide rights to baricitinib licensed to Lilly 6. Approved in multiple territories globally 7. Approved in Japan 8. Worldwide rights to capmatinib licensed to Novartis 9. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 10. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys; exclusive commercialization rights held by Incyte outside the U.S. 11. Approved in Canada 12. European rights to Iclusig licensed from Takeda 13. Licensed from MacroGenics 14. Discovery collaboration with Agenus 15. Development in collaboration with Merus

1L, first-line; 2L+, second-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; mAb, monoclonal antibody; MF, myelofibrosis; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.